Detalles de la búsqueda
1.
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer.
Ann Oncol
; 34(8): 645-659, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37269905
2.
Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial.
Ann Oncol
; 33(3): 299-309, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34861374
3.
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.
Ann Oncol
; 32(8): 983-993, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34272041
4.
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.
Ann Oncol
; 32(2): 197-207, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33186740
5.
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
Ann Oncol
; 32(9): 1148-1156, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34116144
6.
Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.
Ann Oncol
; 31(5): 582-589, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32178964
7.
Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the french real-life curie database.
Breast Cancer Res Treat
; 178(3): 505-512, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31486993
8.
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.
Breast Cancer Res Treat
; 174(3): 719-729, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30632023
9.
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial.
Ann Oncol
; 29(4): 888-894, 2018 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29360932
10.
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.
Ann Oncol
; 29(3): 669-680, 2018 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29342248
11.
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
Ann Oncol
; 29(1): 154-161, 2018 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29045554
12.
Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study.
Breast Cancer Res Treat
; 162(3): 479-488, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28176175
13.
PARP inhibitors and newly second primary malignancies in cancer patients: a systematic review and safety meta-analysis of placebo randomized controlled trials.
Ann Oncol
; 32(8): 1048-1050, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34107345
14.
Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993.
Ann Oncol
; 32(12): 1650, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34740469
15.
Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; volume 32: 983-993.
Ann Oncol
; 32(10): 1308, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34353668
16.
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.
Ann Oncol
; 27(9): 1725-32, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27436849
17.
A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study.
Ann Oncol
; 27(6): 1020-1029, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26916095
18.
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.
Ann Oncol
; 26(1): 113-119, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25355722
19.
Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer.
Ann Oncol
; 26(9): 1904-1910, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26202594
20.
A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours.
Br J Cancer
; 110(9): 2170-7, 2014 Apr 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-24714750